- Previous Close
13,240.00 - Open
13,080.00 - Bid 13,270.00 x --
- Ask 13,350.00 x --
- Day's Range
13,080.00 - 13,540.00 - 52 Week Range
13,080.00 - 20,700.00 - Volume
24,756 - Avg. Volume
122,851 - Market Cap (intraday)
287.208B - Beta (5Y Monthly) 0.47
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 14, 2025 - May 19, 2025
- Forward Dividend & Yield 300.00 (2.24%)
- Ex-Dividend Date Dec 27, 2024
- 1y Target Est
21,000.00
Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.
www.daewonpharm.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 003220.KS
View MorePerformance Overview: 003220.KS
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 003220.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 003220.KS
View MoreValuation Measures
Market Cap
287.21B
Enterprise Value
428.34B
Trailing P/E
17.91
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.43
Price/Book (mrq)
1.04
Enterprise Value/Revenue
0.72
Enterprise Value/EBITDA
9.40
Financial Highlights
Profitability and Income Statement
Profit Margin
2.38%
Return on Assets (ttm)
3.06%
Return on Equity (ttm)
3.68%
Revenue (ttm)
598.16B
Net Income Avi to Common (ttm)
15.27B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
46.11B
Total Debt/Equity (mrq)
65.80%
Levered Free Cash Flow (ttm)
-28.2B